Jefferies Financial Group Inc. Trims Stake in Taysha Gene Therapies, Inc. $TSHA

Jefferies Financial Group Inc. reduced its stake in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 98.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 25,000 shares of the company’s stock after selling 2,131,642 shares during the quarter. Jefferies Financial Group Inc.’s holdings in Taysha Gene Therapies were worth $138,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Marex Group plc purchased a new position in Taysha Gene Therapies during the second quarter valued at approximately $29,000. E Fund Management Co. Ltd. purchased a new position in Taysha Gene Therapies during the second quarter valued at approximately $31,000. Arrowpoint Investment Partners Singapore Pte. Ltd. purchased a new position in Taysha Gene Therapies during the third quarter valued at approximately $40,000. Tower Research Capital LLC TRC raised its position in Taysha Gene Therapies by 156.5% during the second quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company’s stock valued at $41,000 after acquiring an additional 10,742 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its position in Taysha Gene Therapies by 51.9% during the second quarter. BNP Paribas Financial Markets now owns 18,591 shares of the company’s stock valued at $43,000 after acquiring an additional 6,350 shares in the last quarter. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on TSHA. Chardan Capital reiterated a “buy” rating and set a $12.00 price target on shares of Taysha Gene Therapies in a research report on Thursday, March 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Taysha Gene Therapies in a report on Friday, March 27th. Canaccord Genuity Group raised their price objective on Taysha Gene Therapies from $14.00 to $17.00 and gave the company a “buy” rating in a report on Monday, April 6th. Wall Street Zen lowered Taysha Gene Therapies from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, Truist Financial raised Taysha Gene Therapies to a “strong-buy” rating in a report on Wednesday, March 25th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Taysha Gene Therapies has a consensus rating of “Buy” and an average target price of $11.64.

Taysha Gene Therapies Stock Performance

Shares of NASDAQ:TSHA opened at $5.97 on Tuesday. The company has a debt-to-equity ratio of 0.23, a current ratio of 14.04 and a quick ratio of 14.04. The business’s 50 day moving average price is $5.55 and its 200-day moving average price is $5.09. The firm has a market capitalization of $1.72 billion, a PE ratio of -15.71 and a beta of 1.19. Taysha Gene Therapies, Inc. has a 1 year low of $2.25 and a 1 year high of $7.30.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). As a group, equities research analysts expect that Taysha Gene Therapies, Inc. will post -0.47 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Taysha Gene Therapies news, insider Sukumar Nagendran sold 200,000 shares of the business’s stock in a transaction on Friday, April 10th. The stock was sold at an average price of $4.46, for a total transaction of $892,000.00. Following the transaction, the insider owned 1,136,410 shares of the company’s stock, valued at approximately $5,068,388.60. The trade was a 14.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 3.78% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.